Use of polyamine analogs for amyotrophic lateral sclerosis

Details Use of polyamine analogs for amyotrophic lateral sclerosis Use of polyamine analogs for amyotrophic lateral sclerosis

2006-04-18

2006-04-18

Padmanabhan, Sreeni (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S316000, C514S646000

Reexamination Certificate

active

07030126

ABSTRACT:
The present invention provides methods and compositions for modulating polyamine pathway activity as a means for ameliorating neurodegenarative disorders. In particular, for ameliorating the symptoms or onset of amyotrophic lateral sclerosis (ALS) by modulating the gene and protein products involved the polyamine pathway, such as by inhibiting the enzyme, ornithine decarboxylase (ODC), involved in the synthesis of the polyamine, putrescine. Compositions and methods are disclosed for inhibiting the polyamine pathway producing lower polyamine levels resulting in a beneficial effect on ALS. This can be accomplished by using modulating agents such as analogs, or polyamine analogs, and antiproliferative drugs. In particular, the polyamine analog N(1),N(11)-diethylnorspermine (DENSPM) is disclosed as a useful modulating agent in the treatment of ALS. Screening assays for pharmacological agents that are capable of decreasing polyamine levels and/or reducing cell proliferation are also disclosed.

REFERENCES:
patent: 4499072 (1985-02-01), Sunkara et al.
patent: 5541230 (1996-07-01), Basu et al.
patent: 5637768 (1997-06-01), Jund et al.
patent: 5646188 (1997-07-01), Gilad et al.
patent: 5677349 (1997-10-01), Gilad et al.
patent: 5880161 (1999-03-01), Basu et al.
patent: 5886051 (1999-03-01), Bergeron, Jr. et al.
patent: 5962533 (1999-10-01), Bergeron, Jr.
patent: 6166079 (2000-12-01), Follen et al.
patent: 6172261 (2001-01-01), Vermeulin et al.
patent: 6184232 (2001-02-01), Bergeron, Jr.
patent: 6194000 (2001-02-01), Smith et al.
patent: 6235794 (2001-05-01), Bergeron, Jr.
patent: 6277411 (2001-08-01), Shaked et al.
patent: 6342534 (2002-01-01), Bergeron, Jr.
patent: 6392098 (2002-05-01), Frydman et al.
patent: 6423754 (2002-07-01), Holmes-Farley et al.
patent: 6458795 (2002-10-01), Bergeron, Jr.
patent: 6770625 (2003-04-01), Soltero
patent: 0 434 173 (1989-12-01), None
patent: 0 361 687 (1990-04-01), None
patent: 0 436 332 (1991-07-01), None
patent: 0436 332 (1991-07-01), None
patent: 0 950 406 (1999-10-01), None
patent: 0 950 406 (1999-11-01), None
patent: 07024965 (1996-08-01), None
patent: WO 99/08519 (1999-02-01), None
patent: WO 99/21542 (1999-05-01), None
patent: WO 99/65516 (1999-12-01), None
patent: WO 00/66587 (2000-11-01), None
patent: WO 01/85981 (2001-11-01), None
patent: WO 01/85981 (2001-11-01), None
patent: WO 02/053519 (2002-07-01), None
Gonzalez Deniselle, Maria Claudia et al. “Glucocorticoid Receptors And Actions In The Spinal Cord of the Wobbler Mouse, a Model for Neurodegenerative Diseases”, J. Steroid Biochem. Molec. Biol., vol. 60, No. 3-4, pp. 205-213 (1997).
Scorcioni, Francesca et al. “Manipulation of the Expression of Regulatory Genes of Polyamine Metabolism Results in Specific Alterations of the Cell-Cycle Progression” Biochem. J. vol. 354, pp 217-223 (2001).
Thomas T. and Thomas T.J., “Polyamines in Cell Growth and Cell Death: Molecular Mechanisms and Therapeutic Applications”, CMLS, Cell. Mol. Life Sci., vol. 58, pp 244-258 (2001).

Affiliated with

Also associated with

Rating

Use of polyamine analogs for amyotrophic lateral sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of polyamine analogs for amyotrophic lateral sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of polyamine analogs for amyotrophic lateral sclerosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3559414